Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 28:11:1756287219870074.
doi: 10.1177/1756287219870074. eCollection 2019 Jan-Dec.

A review of optimal prostate biopsy: indications and techniques

Justin Streicher  1 , Brian Lee Meyerson  1 , Vidhya Karivedu  2 , Abhinav Sidana  3
Affiliations
Review

A review of optimal prostate biopsy: indications and techniques

Justin Streicher et al. Ther Adv Urol. .

Abstract

Prostate biopsy is the gold standard diagnostic technique for the detection of prostate cancer. Patient selection for prostate biopsy is complex and is influenced by emerging use of prebiopsy imaging. The introduction of the magnetic resonance imaging (MRI)-transrectal ultrasound (TRUS) fusion prostate biopsy has clear advantages over the historical standard of care. There are several biopsy techniques currently utilized with unique advantages and disadvantages. We review and summarize the current body of literature pertaining to when and how a prostate biopsy should be performed. We discuss current recommendations regarding patient selection for biopsy and discuss future directions regarding prebiopsy imaging. We offer a description of the MRI-TRUS fusion biopsy technique and a comparison of many of the currently available fusion software platforms. Articles pertaining to the title were obtained via PubMed index search with relevant keywords supplemented with personal collection of related publications. Prostate biopsy should be considered for patients with gross digital rectal exam (DRE) abnormality, patients with a prostate-specific antigen (PSA) greater than 4 ng/ml, and concomitant risk factors for prostate cancer or patients with lesions identified on multiparametric MRI (mpMRI) with Prostate Imaging Reporting and Data System 2 (PI-RADS2) score of 4 or 5. MRI-TRUS fusion biopsy has demonstrated advantages in cancer detection when compared with TRUS-guided biopsy. There are currently several fusion software platforms available with a variety of biopsy approaches. Future efforts should detail the role of prebiopsy imaging as a triage tool for prostate biopsy. Consensus should be sought regarding the preferred modality of fusion biopsy. Additional data describing each fusion software platform would enable a more rigorous comparison of platform sensitivities.

Keywords: imaging; multiparametric magnetic resonance imaging; prostate cancer; prostate specific antigen; techniques.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

References

    1. American Cancer Society. Cancer facts & figures 2018. Atlanta, GA: American Cancer Society; 2018.
    1. Cooner WH, Mosley BR, Rutherford CL, Jret al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 1146–1152; discussion 1152–4. - PubMed
    1. Coley CM, Barry MJ, Fleming Cet al. Early detection of prostate cancer. Part I: prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med 1997; 126: 394–406. - PubMed
    1. NCCN. Clinical practice guidelines in oncology, prostate cancer early detection. Version 2.2018, https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf (2018). - PubMed
    1. Carter HB, Albertsen PC, Barry MJet al. Early detection of prostate cancer: AUA Guideline. J Urol 2013; 190: 419–426. - PMC - PubMed